CSPCHA115 / CSPC Pharma - LARVOL DELTA

Leaching dynamics of Zn2+, Pb2+ and Cu2+ in urban soils of a semi-arid region: A quantitative analysis. (PubMed, Environ Pollut) - "In the first monitoring period, the IER samplers showed leaching rates of 323.40 g Zn2+ ha-1 15 wk-1, 361.90 g Pb2+ ha-115 wk-1, and 31.9 g Cu2+ ha-115 wk-1...The highest leaching rate of PTEs was identified in the central area of the city and its surroundings, influenced mainly by flood areas and high surface runoff. The results of this study demonstrate the role that monsoon rains and runoff plays in the movement and distribution of PTEs in urban areas."

Journal

The randomized, single- and multiple- ascending dose studies of the safety, tolerability, pharmacokinetics of CSPCHA115 in healthy Chinese subjects. (PubMed, Clin Transl Sci) - "The most common TEAE related to CSPCHA115 was hypertriglyceridemia. No significant safety concerns were identified in healthy subjects."

Clinical • Journal • PK/PD data • Dyslipidemia • Hypertriglyceridemia

Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: Conjupro Biotherapeutics, Inc.; N=120 ➔ 0; Trial completion date: Oct 2024 ➔ Oct 2022; Suspended ➔ Withdrawn; Trial primary completion date: Oct 2024 ➔ Oct 2022

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=120; Suspended; Sponsor: Conjupro Biotherapeutics, Inc.; Trial completion date: Oct 2021 ➔ Oct 2024; Trial primary completion date: Oct 2021 ➔ Oct 2024

Clinical • Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers (clinicaltrials.gov) - P1; N=40; Completed; Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.; Not yet recruiting ➔ Completed

Clinical • Trial completion • Allergic Rhinitis • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=120; Suspended; Sponsor: Conjupro Biotherapeutics; Trial completion date: Oct 2020 ➔ Oct 2021; Not yet recruiting ➔ Suspended; Trial primary completion date: Oct 2020 ➔ Oct 2021

Clinical • Trial completion date • Trial primary completion date • Trial suspension • Asthma • Respiratory Diseases